Prognostic Factors Related to the Mortality Rate of Acute-on-Chronic Liver Failure Patients

Jian Zhang\textsuperscript{1,2,*}
Junfeng Li\textsuperscript{3,*}
Yu Chen\textsuperscript{1,2}
Zhongping Duan\textsuperscript{1,2}

\textsuperscript{1}Difficult & Complicated Liver diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China; \textsuperscript{2}Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, People’s Republic of China; \textsuperscript{3}The First Hospital of Lanzhou University, Department of Infectious Diseases, Lanzhou, People’s Republic of China

*These authors contributed equally to this work

Background: Critical illness-related corticosteroid insufficiency (CIRCI) is known to be a common complication in patients with acute-on-chronic liver failure (ACLF). However, factors that predict the survival rate of ACLF patients remain unclear. The present study aims to determine the prognostic factors that impinge on the survival rate of ACLF patients.

Methods: A total of 90 patients with ACLF at different stages, with or without CIRCI, were prospectively evaluated.

Results: Various clinical factors were found to be significantly different among patients at early, mid and late stages of ACLF, as well as between the same population of patients with and without CIRCI. Specifically, patients at later stages of ACLF and patients with CIRCI had significantly higher Child–Turcotte–Pugh (CTP), Model for End-Stage Liver Disease (MELD) and ACLF Research Consortium (AARC)-ACLF scores. CIRCI was observed in 20% of the enrolled patients (18 out of 90). In addition, the 90-day mortality rate was higher in mid- and late-stage ACLF patients, as well as patients with CIRCI.

Conclusion: ACLF stage and CIRCI predict early mortality in patients with ACLF and could be actively monitored in these patients for prioritized liver transplantation.

Keywords: CIRCI, liver failure, mortality, stage

Introduction

Acute-on-chronic liver failure (ACLF) was first proposed by Dr. Ohnishi in 1995 to describe a group of acute injury symptoms established on top of chronic liver disease.\textsuperscript{1} Virus, bacterial and fungal infection, alcoholism and drug damage are all common causes of ACLF. Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition) published by the Chinese Society of Infectious Diseases proposed that ACLF is histopathologically manifested as the presence of newly identified liver cell necrosis at varying degrees on the basis of chronic liver failure.\textsuperscript{2} ACLF develops on top of chronic liver diseases due to various reasons, including acute jaundice deepening and coagulation dysfunction as syndromes manifested by liver failure. Other associated complications include hepatic encephalopathy, ascites, electrolyte imbalance, infection, hepatorenal syndrome, hepatopulmonary syndrome, and failure of extrahepatic organs. ACLF often progresses rapidly, with high short-term mortality rate and poor prognosis. So far, liver transplantation is the only effective treatment against ACLF. However, its clinical application is often limited due to the lack of liver source and high treatment costs. Therefore, prognosis of ACLF becomes extremely important to prevent the disease progression at early stage.

Due to the complicated conditions of liver failure, single indicators are not sufficient for prognosis and often cannot fully reflect liver function. Currently, the
commonly used clinical prognostic scores include Child–
Turcotte–Pugh (CTP), Model for End-Stage Liver
Disease (MELD), MELD-Na and CLIF-SOFA. In
2017, the Asian Pacific Association for the Study of the
Liver (APASL) established the ACLF Research
Consortium (AARC)–ACLF score system that was super-
ior to the previous ones in predicting mortality based on
Asian population. It was proposed based on the total
bilirubin, creatinine, serum lactate, INR and hepatic ence-
phalopathy levels that were identified as independent pre-
dictors of mortality in ACLF patients.

Relative adrenal insufficiency (RAI) is a condition
characterized by the failure of the adrenal gland to produce
sufficient amounts of steroid hormones, primarily cortisol,
to meet the peripheral requirements. It is first observed in
critically ill cirrhotic patients in 1960. Later studies have
shown that RAI is closely associated with the onset of
cirrhosis. In addition, it is tightly correlated with com-
promised liver function and sharply elevated short-term
mortality. The term RAI is later replaced by critical
illness-related corticosteroid insufficiency (CIRCI), which
is initially proposed by the Society of Critical Care
Medicine in 2008 to describe disruption of the hypothala-
mic–pituitary–adrenal (HPA) axis during critical illness.

In the present prospective cohort study, we aim to
identify the prognostic factors that are related to the survi-
val of ACLF patients. Specifically, our question is whether
the presence of CIRCI, regardless of the stage of liver
dysfunction, is associated with short-term mortality.

Methods
Patients

The study was approved by the review board of Beijing
Youan Hospital of Capital Medical University. Verbal con-
sent was obtained from all included patients or their rela-
tives. Verbal informed consent was approved by the ethical
committee, and the study was conducted in accordance
with the Declaration of Helsinki. The present prospective
cohort study enrolled 105 patients with ACLF at Beijing
Youan Hospital from May 2019 to October 2020. ACLF
was diagnosed according to clinical manifestation, labora-
tory data and compatible abdominal imaging criteria.

The stage of ACLF was determined as previously
described. Specifically, early-stage ACLF develops on
the basis of chronic non-cirrhotic liver disease. Patients
at early ACLF stage exhibited extreme fatigue and severe
gastrointestinal symptoms, such as anorexia, vomiting and
abdominal distension. Serum total bilirubin was found to
be over 10 mg/dL or with a daily increase over 1 mg/dL.
Patients demonstrated bleeding tendency, with prothrom-
bin time (PT) (international normalized ratio (INR)) value
between 1.5 and 1.9. No other complications or extrahe-
patch organ failure were observed.

The mid-stage ACLF develops on the basis of com-
pensated liver cirrhosis, normally within 4 weeks. Patients
at mid-ACLF stage demonstrated obvious bleeding with
bleeding spots or ecchymosis and the PT (INR) value was
between 1.9 and 2.6. Patients also demonstrated one com-
plication and/or extrahepatic organ failure.

Late-stage ACLF develops on the basis of decompens-
ated liver cirrhosis. Patients at late ACLF stage severe
bleeding with ecchymosis at the injection site and the PT
(INR) value was greater than 2.6. Patients also showed
more than two or more complications and/or extrahepatic
organ failure.

All included patients were between the age of 40 and
70. None of the patients were alcoholics or drug abusers
and demonstrated stable haemodynamic parameters.
Patients with tumors and dysfunction originated from fail-
ure in other organs were excluded from the study. No
patients were taking any cortisol-related medication during
the study period. Chronic adrenal insufficiency was ruled
out in these patients by physical examinations, CT scan
and track of their medical history. As a result, 15 patients
were excluded from the initial enrollment.

Baseline Evaluation

An initial clinical evaluation on the day of admission was
performed on all included patients, including measurement
of blood pressure, pulse and respiratory rate and body
temperature, as well as abdominal CT scan, electrocardio-
gram, liver and kidney function tests, measurement of
serum high-density lipoprotein (HDL) and urine test.
Routine biochemistry, hematology and coagulation profiles
were also performed on the day of admission. The severity
of liver failure was graded by CTP, MELD and AARC-
ACLF scores.

Determination of CIRCI

CIRCI was determined using the short corticotropin
stimulation test (SST) as previously described. Briefly,
synthetic adrenocorticotropic hormone (ACTH) was deliv-
ered intravenously. A high dose ACTH stimulation test
(250 mg) was used for the diagnosis of adrenal insuffi-
ciency. Blood sample was collected and cortisol levels
were assessed immediately before and 30 and 60 min after the administration of ACTH. CIRCI was determined if the peak serum cortisol level was less than 18 µg/dl or the delta fraction was less than 9 µg/dl.

**Follow-Up**

All patients were followed for 90 days since the day of hospital admission. Telephone communication or interview at the outpatient department was conducted on 7, 14, 28, 60, and 90 days after diagnosis.

**Statistical Analysis**

Quantitative data were presented as median plus range and analyzed by the Mann–Whitney U or One-way ANOVA following post-hoc test. A P value of less than 0.05 was considered as statistically significant. Survival analysis was assessed by the Kaplan–Meier curve and compared by the Log rank test. Univariate analysis of baseline factors was performed to predict the 90-day mortality. Factors that were identified as statistically significant were entered into multivariate analysis by binary logistic regression with the backward conditional method for further analysis.

Statistical analysis was conducted using the GraphPad Prism software (GraphPad Software Inc.) and SPSS 16.0 software (SPSS Inc.).

**Results**

**Comparison of Patient Characteristics Among the Early, Mid and Late Liver Failure Stage Groups**

A total of 105 consecutive patients diagnosed with liver failure were admitted to our institution and screened for the enrollment into the present study. Eventually, 15 patients were excluded according to the exclusion criteria. The remaining 90 patients were separated into 3 groups based on the stage of ACLF, ie early, mid and late stages. The clinical characteristics of all included patients are listed in Table 1.

Of the 90 patients, 64% (58 out of 90) of them were male. A significant difference in age was observed among the 3 groups, where patients in the early-stage group were much younger than the ones in the other two groups (Table 1). Alcohol and HBV infection were found to be the major causes of liver failure for patients in all 3 groups (Table 1). In addition, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, albumin, hemoglobin, high-density lipoprotein (HDL) levels, platelet count, CTP, MELD and AARC-ACLF scores were all significantly different among the 3 groups (Table 1). Since the stages of ACLF were determined based on the prothrombin time (PT), it was certainly significantly different among the three groups (Table 1). In terms of cortisol level, basal, peak or the difference between the two were not significantly different among the 3 groups (Table 1). Only 1 patient in the early stage was determined to suffer CIRCI, whereas 10 and 7 patients met the CIRCI standard in the mid- and late-stage groups, respectively (Table 1).

**Comparison of Characteristics Between Patients with and without CIRCI**

Next, we regrouped the 90 patients into 2 groups based on the presence of CIRCI, ie patients with CIRCI and patients without CIRCI. CIRCI was diagnosed in 18 of the patients (20%). By comparing the clinical characteristics between the two groups of patients, we found that serum AST, bilirubin, albumin, hemoglobin levels, CTP, MELD and AARC-ACLF scores, basal, peak and delta fraction of cortisol levels were all significantly different (Table 2). This suggests that onset of CIRCI is closely related to reduced liver function.

**Mortality and CIRCI**

The patients were followed for 90 days upon institution admission. 36 patients have passed away during this follow-up period, where 22 of them (22 out of 72, 30.6%) were from the CIRCI-negative group and the other 14 (14 out of 18, 77.8%) were from the CIRCI-positive group (Figure 1A). When looking from the stage-grouping perspective, 2 (2 out of 30, 6.7%) were from the early-stage group, 10 (10 out of 30, 33.3%) were from the mid-stage group and 24 (24 out of 30, 80%) were from the late-stage group (Figure 1B). It is worth noting that all survivors did not receive orthotopic liver transplantation. The major causes of death were progressive liver failure and sepsis for both grouping conditions (Tables 3 and 4). We also performed Kaplan–Meier curve analysis to compare patient survival between the CIRCI-negative and CIRCI-positive groups, as well as among the early, mid and late-stage groups. A significant difference was observed in both comparisons (Figure 1C and D). Taken together, these data suggest the mortality risk was much higher in the ACLF patients with CIRCI than in those without CIRCI, and much higher in patients at late and mid stages of ACLF than in those at early stage.
Table 1 Clinical Characteristics of the Patients at Early, Mid and Late Stages of ACLF

| Characteristic | ACLF (n=90) | Early Stage (n=30) | Mid Stage (n=30) | Late Stage (n=30) | P value |
|----------------|-------------|--------------------|------------------|-------------------|---------|
| Age (years)    |             |                    |                  |                   | 0.0289  |
| Male           |             |                    |                  |                   |         |
| Female         |             |                    |                  |                   |         |
| Cause          |             |                    |                  |                   |         |
| HBV            |             |                    |                  |                   |         |
| HCV            |             |                    |                  |                   |         |
| HBV+HCV        |             |                    |                  |                   |         |
| Alcohol        |             |                    |                  |                   |         |
| Other          |             |                    |                  |                   |         |
| AST (U/L)      | 43.3 (27.1–54.4) | 53.35 (40.1–68) | 67.6 (55.8–83.9) | <0.0001           |
| ALT (U/L)      | 22.5 (15–29.7)    | 33.7 (21.1–39.7) | 43.2 (30.1–49.8) | <0.0001           |
| Bilirubin (mg/dL) | 2.55 (2–3)     | 3.6 (3–4.5)       | 4.1 (3.6–4.9)    | <0.0001           |
| Albumin (g/dL) | 3.1 (2.5–4)    | 2.5 (2–3.5)       | 2.5 (2–2.9)      | <0.0001           |
| PT (INR)       | 1.7 (1.5–1.9)  | 2.4 (2–2.6)       | 2.9 (2.7–3)      | <0.0001           |
| Leukocytes (x10⁹/L) | 4.75 (1.7–7.7) | 4.65 (1.7–7.6)   | 4.35 (1.8–7.6)   | 0.9893            |
| Hemoglobin (g/dL) | 12.45 (11–13)  | 10.6 (9–12)       | 9.95 (9–11)     | <0.0001           |
| Platelet count (x10⁹/L) | 82.8 (55.4–145.4) | 114.55 (46.7–144) | 87.75 (47.9–145.5) | <0.0001 |
| Na (mmol/L)    | 141.35 (135.7–144.8) | 139.8 (135–145) | 140.55 (135.7–144.9) | 0.2663 |
| K (mmol/L)     | 4.2 (3–4.9)   | 4 (3.2–4.9)       | 4.25 (3–5)       | 0.6756            |
| BUN (mg/dL)    | 13.75 (9.5–16.9) | 12.55 (8–17)     | 12.9 (8.2–16.9)  | 0.5030            |
| Creatinine (mg/dL) | 0.8 (0.5–1)   | 0.8 (0.5–1)      | 0.7 (0.5–1)      | 0.6327            |
| HDL (mg/dL)    | 24.55 (20–32.4) | 29.15 (20.1–39.8) | 36.15 (24.7–49.2) | <0.0001 |
| CTP score      | 7 (6–8)       | 9 (7–10)          | 9 (7–11)         | <0.0001           |
| CTP class      |             |                    |                  |                   |         |
| A              | 10 (33.3%)  | 0 (0%)            | 0 (0%)           | <0.0001           |
| B              | 20 (66.7%)  | 21 (70%)          | 18 (60%)         | <0.0001           |
| C              | 0 (0%)      | 9 (30%)           | 12 (40%)         | <0.0001           |
| MELD score     | 13 (10–15)   | 15.5 (10–25)      | 19.5 (15–25)     | <0.0001           |
| AARC-ACLF score | 6 (5–8)   | 10 (7–11)         | 12 (9–15)        | <0.0001           |
| Basal cortisol (µg/dL) | 10.8 (8.5–15) | 11.4 (8.1–15.7) | 11.8 (8.1–16) | 0.5141 |
| Peak cortisol (µg/dL) | 26.1 (19.7–32.4) | 23.7 (17.1–39.3) | 24.9 (15.5–34.3) | 0.9646 |
| Delta fraction cortisol (µg/dL) | 15.6 (8–21.4) | 12.2 (4.4–31.2) | 13.5 (5.6–22.3) | 0.8427 |
| CIRCI (%)      | 1 (3.3%)    | 10 (33.3%)        | 7 (23.3%)        |         |

Note: Data are presented as median (range) or actual number (percentage).
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; BUN, blood urea nitrogen; HDL, high-density lipoprotein; CTP, Child–Turcotte–Pugh; MELD, Model For End-Stage Liver Disease; CIRCI, critical illness-related corticosteroid insufficiency; INR, international normalized ratio.
Table 2 Clinical Characteristics of the ACLF Patients with and without CIRCI

| Characteristic     | Patients without CIRCI (n=72) | Patients with CIRCI (n=18) | P value |
|-------------------|-------------------------------|---------------------------|---------|
| Age (years)       | 52 (41–69)                    | 56 (40–69)                | P=0.4287|
| AST (U/L)         | 52.4 (27.1–83.9)              | 62.8 (41.9–80.4)          | P=0.0162|
| ALT (U/L)         | 31.4 (15–49.8)                | 34.3 (22.3–49.3)          | P=0.1234|
| Bilirubin (mg/dL) | 3.5 (2–4.9)                   | 3.9 (2.5–4.9)             | P=0.0194|
| Albumin (g/dL)    | 2.8 (2–4)                     | 2.3 (2.2–3.3)             | P=0.0142|
| PT (INR)          | 2.3 (1.5–3)                   | 2.6 (1.6–3)               | P=0.0796|
| Leukocytes (x109/L) | 4.5 (1.7–7.7)         | 5.1 (1.8–7.2)             | P=0.8842|
| Hemoglobin (g/dL) | 11 (9–13)                     | 10.6 (9–11.7)             | P=0.0300|
| Platelet count (x109/L) | 93.5 (46.7–145.4) | 115.2 (54.1–145.5)       | P=0.0577|
| Na (mmol/L)       | 140.9 (135.5–144.9)          | 139.4 (135–145)           | P=0.1913|
| K (mmol/L)        | 4.1 (3–5)                     | 4 (3.2–4.8)               | P=0.6468|
| BUN (mg/dL)       | 12.7 (8–17)                   | 13.4 (8.6–17)             | P=0.5344|
| Creatinine (mg/dL)| 0.8 (0.5–1)                   | 0.6 (0.5–1)               | P=0.1022|
| HDL (mg/dL)       | 28.5 (20–49.2)                | 30.7 (20.4–42.3)          | P=0.4787|
| CTP score         | 8 (5.5–10.4)                  | 9.4 (6–10.5)              | P=0.0075|
| MELD score        | 15 (10–25)                    | 19 (10–25)                | P=0.0280|
| AARC-ACLF score   | 9 (5–15)                      | 11 (6–15)                 | P=0.0322|
| Basal cortisol (µg/dL) | 10.9 (8.1–16)        | 13.3 (8.1–15.7)           | P=0.0012|
| Peak cortisol (µg/dL) | 27.2 (18.8–39.3)     | 19.35 (15.5–24.2)         | <0.0001|
| Delta fraction cortisol (µg/dL) | 15.9 (8.6–31.2) | 6.3 (4.4–8.7)             | <0.0001|

Note: Data are presented as median (range) or actual number (percentage).

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; BUN, blood urea nitrogen; HDL, high-density lipoprotein; CTP, Child–Turcotte–Pugh; MELD, Model For End-Stage Liver Disease; CIRCI, critical illness-related corticosteroid insufficiency; INR, international normalized ratio.

Cox regression analysis of factors that predict the 90-day survival rate revealed that serum albumin, hemoglobin and HDL levels, CTP, MELD and AARC-ACLF scores, as well as delta fraction cortisol level were significantly related factors in univariate analysis (Table 5).

Discussion

In the present study, we employed the peak serum cortisol level that is less than 18 µg/dl or the delta fraction that is less than 9 µg/dl as criteria to determine CIRCI in ACLF patients. With that, we revealed 20% (18 out of 90) CIRCI in these patients at different stages. A number of methods have been developed to evaluate adrenal function, including assessing cortisol levels after insulin-induced hypoglycemia, or administration of ACTH, or corticotropin-releasing hormone. The CIRCI frequency of 20% identified in this study falls within the previously published range of similar studies. Several potential underlying mechanisms that correlate CIRCI with liver failure have been previously proposed, including 1) liver dysfunction that lowers serum cholesterol level and subsequent reduced cortisol biosynthesis, 2) excessive production of proinflammatory cytokines that suppresses adrenal steroid production and 3) circulatory dysfunction that leads to adrenal hypoperfusion. In general, our results agree with the first mechanism since CIRCI was tightly correlated with more advanced ACLF and lower serum HDL level. The finding that CIRCI patients had a significantly lower level of hemoglobin suggests that CIRCI might be associated with the circulatory dysfunction commonly observed in late-stage liver failure patients. Therefore, it is likely that the development of CIRCI in ACLF is a combination of different mechanisms, instead of a single factor.

For personal use only.
Another important finding of the present study is the positive correlation between the stage of ACLF and 90-day mortality, as well as CIRCI and 90-day mortality. Importantly, the presence of CIRCI is independently associated with the short-term mortality, regardless of the stage of liver dysfunction. To the best of our knowledge, our study is the first to investigate the impact of ACLF stage on mortality. The findings that CIRCI is associated much higher mortality rate are consistent with several previous studies. Therefore, CIRCI appears to be a critical test for liver failure patients at different stages to direct further treatment and precautions.

There are a few limitations associated with the present study. First, the analyzed patient number was relatively small. [Table 3] and [Table 4] show the causes of death among patients with and without CIRCI, and at different stages of ACLF, respectively.

![Figure 1](https://doi.org/10.2147/DMSO.S309641)

Figure 1 Survival analysis of patients at early, mid and late stages of ACLF and patients with and without CIRCI. (A and B) Survival outcome of CIRCI-negative and CIRCI-positive patients (A) and patients at early, mid and late stages of ACLF (B). (C and D) Kaplan-Meier curves showing survival of patients with and without CIRCI (C) and patients at early, mid and late stages of ACLF (D); and compared with the Log rank test.

**Table 3** Cause of Death of the ACLF Patients with and without CIRCI

| Cause of Death           | Patients Died without CIRCI (n=22) | Patients Died with CIRCI (n=14) |
|--------------------------|-----------------------------------|---------------------------------|
| Progressive liver failure| 10 (45.5%)                        | 6 (42.9%)                      |
| Sepsis                   | 6 (27.3%)                         | 4 (28.6%)                      |
| Gastrointestinal bleeding| 2 (9.1%)                          | 2 (14.3%)                      |
| Hepatorenal syndrome     | 2 (9.1%)                          | 1 (7.1%)                       |
| Hepatocellular carcinoma | 2 (9.1%)                          | 1 (7.1%)                       |

*Note: Data are presented as actual number (percentage).*

**Table 4** Cause of Death of the Patients at Early, Mid and Late Stages of ACLF

| Cause of Death            | Early Stage (n=2) | Mid Stage (n=10) | Late Stage (n=24) |
|---------------------------|-------------------|------------------|-------------------|
| Progressive liver failure | 1 (50%)           | 5 (50%)          | 11 (45.8%)        |
| Sepsis                    | 1 (50%)           | 2 (20%)          | 7 (29.2%)         |
| Gastrointestinal bleeding | 0 (0%)            | 0 (0%)           | 2 (8.3%)          |
| Hepatorenal syndrome      | 0 (0%)            | 1 (10%)          | 2 (8.3%)          |
| Hepatocellular carcinoma  | 0 (0%)            | 1 (10%)          | 2 (8.3%)          |

*Note: Data are presented as actual number (percentage).*
Table 5 Cox Regression Univariate Analysis of Factors Predicting 90-Day Mortality

| Characteristic     | HR     | 95% CI       | P value |
|--------------------|--------|--------------|---------|
| Age                | 1.032  | 0.913–1.098  | 0.751   |
| Male               | 0.812  | 0.219–2.342  | 0.721   |
| AST                | 0.992  | 0.943–1.135  | 0.397   |
| ALT                | 0.917  | 0.945–1.178  | 0.362   |
| Bilirubin          | 1.204  | 0.931–1.465  | 0.169   |
| Albumin            | 0.053  | 0.022–0.479  | 0.004   |
| PT (INR)           | 6.332  | 2.467–15.963 | 0.078   |
| Leucocytes         | 1.021  | 0.954–1.089  | 0.384   |
| Hemoglobin         | 0.714  | 0.457–0.986  | 0.022   |
| Platelet count     | 1.004  | 0.941–1.187  | 0.379   |
| Na                 | 0.941  | 0.798–1.096  | 0.642   |
| K                  | 0.865  | 0.694–0.973  | 0.514   |
| BUN                | 0.798  | 0.675–1.085  | 0.473   |
| Creatinine         | 9.765  | 2.81–18.645  | 0.097   |
| HDL                | 0.978  | 0.896–0.998  | 0.012   |
| CTP score          | 1.573  | 1.153–2.123  | 0.002   |
| MELD score         | 1.187  | 1.021–1.375  | 0.008   |
| AARC-ACLF score    | 1.346  | 1.045–1.875  | 0.003   |
| Delta fraction cortisol | 0.824 | 0.692–0.948  | 0.001   |

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; BUN, blood urea nitrogen; HDL, high-density lipoprotein; CTP, Child–Turcotte–Pugh; MELD, Model For End-Stage Liver Disease; INR, international normalized ratio.

limited, due to the nature of this single-center study. Future studies involving multiple centers with larger patient numbers would be needed to strengthen the findings. Second, we did not manage to assess direct hemodynamic parameters and serum cytokine levels to test the involvement of inflammation mechanisms on adrenal production of steroids and its relation to CIRCI and liver failure. Third, due to increased sex hormone-binding globulin (SHBG) under liver dysfunction conditions, free cortisol might be normal even in the presence of low total cortisol. Therefore, further study measuring free urine cortisol level in these patients may solidify the conclusion of the current study. Fourth, the follow-up period is relatively short, although an overall 40% mortality rate (36 out of 90) were reached after 90 days of follow-up.

In summary, we have identified a number of clinical factors that were significantly different in patients at different stages of ACLF, as well as in the patients with or without CIRCI. Our data demonstrate that the prevalence of CIRCI is positively correlated with the severity of ACLF. In addition, both ACLF stages and onset of CIRCI are important predictors for the 90-day mortality rate.

Abbreviations
HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; BUN, blood urea nitrogen; HDL, high-density lipoprotein; CTP, Child–Turcotte–Pugh; MELD, Model For End-Stage Liver Disease; RAI, relative adrenal insufficiency; INR, international normalized ratio.

Data Sharing Statement
All data generated or analyzed during this study are included in this published article.

Ethics Approval and Consent to Participate
The study protocol was approved by Beijing Youan Hospital of Capital Medical University. Verbal consent was obtained from each patient at the time of admission. The purpose and design of the study were carefully explained to all individual participants accompanied by their close relatives before consent was obtained according to the guidance provided by the ethical committee. The patients provided their written informed consent to participate in this study.

Consent for Publication
All authors read and approved the final manuscript.

Acknowledgment
The study was supported by Beijing Key Lab Open Project Funding (BJYAHKF2017007).

Author Contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work.

Funding
Beijing Key Lab Open Project Funding (BJYAHKF2017007).

Disclosure
The authors declare that they have no competing interests.
References

1. Ohnishi H, Sagihara J, Moriwaki H, et al. [Acute-on-chronic liver failure]. Nihon Ronen Igakkai Zasshi. 1995;7(7):217–219. [In Japanese]

2. Okuda K, Shikama T, Shirai S. Chronic liver disease and liver cirrhosis in the world. J Gastroenterol. 1993;28(3):142–149.

3. Pugh RN, Murray-Lyon I, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. doi:10.1002/bjs.1800600817

4. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–871. doi:10.1053/he.2000.5852

5. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652–1660. doi:10.1053/j.gastro.2006.02.010

6. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–U189. doi:10.1053/j.gastro.2013.02.042

7. Choudhary A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461–471. doi:10.1111/tvh.12840

8. Peterson RE. Adrenocortical steroid metabolism and adrenal cortical function in liver disease. J Clin Invest. 1960;39(2):320–331. doi:10.1172/JCI104043

9. Harry R, Auzinger G, Wendum D. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology. 2002;36(2):395–402.

10. McDonald JA, Handelsman DJ, Dilswoth P, et al. Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. J Gastroenterol Hepatol. 1993;8(3):247–53. doi:10.1111/j.1440-1746.1993.tb01195.x

11. Tsai MH, Peng Y-S, Chen Y-C, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673–81. doi:10.1002/hep.21101

12. Acevedo J, Fernández J, Prado V, et al. Relative adrenal insufficiency in decompensated cirrhosis: short-term risk to halftime of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013;58(5):1757–65. doi:10.1002/hep.26535

13. Fede G, Spadaro L, Tomasselli T, et al. Assessment of adrenocortical reserve in stable patients with cirrhosis. J Hepatol. 2011;54(2):243–50. doi:10.1016/j.jhep.2010.06.034

14. Thievon T, Borot S, Remy-Martin A, et al. Assessment of adrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol. Liver Int. 2011;31(3):425–33. doi:10.1111/j.1478-3231.2010.02431.x

15. Marik PE, McDonald JA, Handelsman DJ, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937–49. doi:10.1097/CCM.0b013e31817603ba

16. Huang XF, Hu W, He XJ, Zhang GS. A potential diagnostic protocol for critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients. J Eur Crit Care Med. 2018;2:86. doi:10.21037/jeccm.2018.10.11

17. Fede G, Spadaro L, Tomasselli T, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012;55(4):1282–91. doi:10.1002/hep.25573

18. Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–53. doi:10.1210/jc.2008-0710

19. Chawlani R, A Arora, P Ranjan, et al. Adrenal insufficiency predicts early mortality in patients with cirrhosis. United European Gastroenterol J. 2015;3(6):529–38. doi:10.1177/2050606915561103

20. Jang JY, Kim TY, Sohn JH, et al. Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality. Aliment Pharmacol Ther. 2014;40(7):819–26. doi:10.1111/apt.12891

21. Tan T, Chang L, Woodward A, et al. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol. 2010;53(5):841–8. doi:10.1016/j.jhep.2010.05.020

22. Fernandez J, A Escorsell, M Zabalza, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology. 2006;44(5):1288–95.